Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication
Fig 7
Effect of PASylated IFN-1ant on plasma VL rebound upon ART interruption.
Log10 Plasma SIV RNA levels measured up to 15 weeks after ART interruption (25 weeks after PASylated IFN-1ant/placebo) in macaques previously treated from weeks 16–24 p.i. with placebo saline (n = 9), IFN-1ant injections 2 times weekly (IFN-1ant2x; n = 11) or 3 times weekly (IFN-1ant3x; n = 5). Delayed IFN-1ant 3x macaques (n = 5) received antagonist treatment from 35–43 p.i. Error bars indicate geometric SD and a dotted line indicates the LLQ (lower limit of quantification).